Veeva Systems Inc. — Form 10-Q Summary
Business context and period. Veeva provides cloud software, data, analytics, and services, primarily to the life sciences industry. This filing covers the fiscal second quarter and first six months ended July 31, 2023; the fiscal year ends January 31. Comparisons below are with the same periods in 2022 unless noted.
Financial performance and position
| Metric | Quarter | Six months |
|---|---|---|
| Total revenue | $590.2 million, up 10% | $1,116.6 million, up 7% |
| Subscription revenue | $470.6 million, up 10% | $885.2 million, up 6% |
| Professional services and other revenue | $119.6 million, up 13% | $231.4 million, up 11% |
| Gross profit / margin | $421.2 million / 71% (72% prior year) | $780.9 million / 70% (72% prior year) |
| Operating income | $104.0 million, versus $101.1 million | $165.6 million, versus $228.8 million |
| Net income | $111.6 million, versus $90.6 million | $243.1 million, versus $190.7 million |
| Diluted GAAP EPS | $0.68, versus $0.56 | $1.49, versus $1.17 |
| Operating cash flow | $265.0 million, versus $93.4 million | $771.0 million, versus $574.4 million |
- Revenue growth in the quarter included $35 million of subscription growth from R&D Solutions and $7 million from Commercial Solutions. Professional services growth was weighted toward R&D implementation and deployment work.
- Operating income for the six months declined despite higher revenue, as operating expenses rose substantially. Research and development expense increased 23% and total operating expenses increased 18% year over year.
- Other income, net was $38.8 million for the quarter and $69.1 million for the six months, mainly reflecting higher interest income. The six-month tax benefit of $8.5 million included $68 million of excess tax benefits from equity compensation, primarily associated with the CEO’s February 2023 option exercise. The six-month effective tax rate was negative 3.6%.
- Stock-based compensation was $102.9 million for the quarter and $193.6 million for the six months. Non-GAAP diluted EPS was $1.21 and $2.12, respectively; these measures exclude stock compensation and purchased-intangible amortization, among other adjustments.
- At July 31, cash and cash equivalents were $742.6 million and short-term investments were $3.126 billion, totaling about $3.87 billion. Total assets were $5.23 billion and stockholders’ equity was $4.15 billion. The balance sheet reports no borrowings; liabilities include deferred revenue and lease obligations.
- Operating cash flow benefited from collections and the timing of income-tax payments. Management notes that first-quarter operating cash flow is seasonally strongest and expects substantially lower quarterly cash flow later in fiscal 2024. Investing cash use largely reflected purchases of short-term investments.
- Deferred revenue was $836.5 million, down from $869.3 million at January 31. Remaining subscription performance obligations were approximately $1.088 billion; about 94% was expected to be recognized within 12 months.
Material changes, outlook, and risks
- Outlook: Management expects fiscal 2024 total and subscription revenue growth to decline versus fiscal 2023, and operating margin to decrease, reflecting contract changes and continued investment and hiring. It expects revenue growth to accelerate in fiscal 2025 compared with fiscal 2024, while noting that part of the acceleration reflects the fiscal 2024 revenue impact described below.
- Effective February 1, 2023, master subscription agreements governing multi-year orders generally give customers a termination-for-convenience right. This changes revenue-recognition timing, reduces fiscal 2024 revenue, and has made related contract assets immaterial. From fiscal 2025, revenue on such orders is generally expected to align more closely with invoicing.
- The company expects the research-and-development tax capitalization rules to reduce fiscal 2024 operating cash flow by approximately $90 million. It also expects foreign exchange to negatively affect fiscal 2024 revenue in U.S. dollars.
- Management expects near-term cost increases in subscription delivery and professional services, as well as higher R&D, sales and marketing, and administrative expenses. It expects other income to remain higher for the rest of fiscal 2024, primarily due to interest rates. A new annual inflation adjustment in qualifying new or renewed orders is capped at the lower of 4% or the specified CPI measure; management does not expect a significant fiscal 2024 revenue effect.
- Veeva plans to move its multichannel CRM applications from Salesforce to its Vault platform. Vault CRM was first sold to an early adopter in August 2023; general availability was planned for April 2024. Existing CRM customers are required to migrate by September 1, 2030. Migration execution, customer retention, and the end of Salesforce agreement protections are significant risks.
- Key contingencies include ongoing IQVIA litigation, with discovery largely complete and expert discovery expected to conclude by the end of October 2023, and a Mednet case in discovery with trial set for early 2024. The company says it cannot meaningfully estimate potential loss ranges. Medidata’s appeal followed a trial-court judgment in Veeva’s favor. No success-fee liability for IQVIA litigation had been accrued.
- Other risks include cybersecurity and service disruptions, competition and customer concentration, life-sciences industry spending and sales-representative reductions, privacy and regulatory requirements, foreign exchange, and interest-rate exposure. A 100-basis-point rate increase was estimated to reduce the investment portfolio’s market value by $36 million. The company reported effective disclosure controls and no material quarter changes to internal control over financial reporting.
Important facts for investors to verify
- How revenue growth and subscription performance develop after the multi-year contract termination-right changes, especially the expected fiscal 2025 comparison.
- Whether the planned Vault CRM launch and customer migration proceed on schedule, and how they affect renewals, customer retention, and margins.
- Underlying profitability and cash generation after considering substantial stock-based compensation and the one-time-sensitive equity tax benefits; also monitor expected tax-related cash outflows.
- Progress and potential outcomes of IQVIA, Mednet, and other litigation; the filing provides no clear estimate of possible losses for key cases.
- Changes in investment portfolio fair value and interest income, as well as foreign-exchange effects and exposure to customer or industry spending reductions.